ARTICLE DOWNLOAD

JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)

10$
ARTICLE DOWNLOAD

JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)

10$

Hitoshi Kiyoi, Hiroki Yamaguchi, Yoshinobu Maeda & Takahiro Yamauchi 

Overview

Pathology and treatment of AML

Acute myeloid leukemia (AML) is a highly diverse hematologic malignancy characterized by autonomous clonal proliferation of immature myeloid cells that are unable to differentiate or mature normally. Abnormal proliferation of leukemic cells in the bone marrow markedly impairs normal hematopoiesis, causing various symptoms associated with leukopenia, anemia, and thrombocytopenia. It is a serious disease that can lead to death from infection or hemorrhage in a short period of time if not treated properly.

The basic treatment strategy for newly diagnosed AML is intensive curative chemotherapy based on a combination regimen. However, the patient’s ability to tolerate organ toxicity and complications of chemotherapy must be carefully and rigorously determined with consideration to their age, organ function, and general condition when deciding whether the patient is a candidate (Table 1) [1, 2]. Chemotherapy for AML consists of induction therapy and postremission therapy, which is performed after remission is achieved. Patients who do not have a favorable long-term prognosis with chemotherapy alone are candidates for allogeneic hematopoietic stem cell transplantation (HSCT) in first remission.

Only units of this product remain
Year PDF
Language English
Format PDF
DOI 10.1007/s12185-020-02856-3